SEP 4, 2026 · PHASE 1/2 TRIAL
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
ClinicalTrials.gov
Early-phase trial (Phase 1/2) with no reported results; registry record describes planned study design and endpoints only, typical of first-in-human or dose-escalation work.
Reported
Planned enrollment350
Study phasePhase 1/2
Primary outcome measure (dose-fin…Recommended Phase 2 Dose (RP2D) at 12 months